Literature DB >> 21083965

The test of everyday attention reveals significant sustained volitional attention and working memory deficits in friedreich ataxia.

Felicity Klopper1, Martin B Delatycki, Louise A Corben, John L Bradshaw, Gary Rance, Nellie Georgiou-Karistianis.   

Abstract

Sustained volitional attention and working memory capacity was examined for the first time in people with Friedreich ataxia (FRDA). We administered subtests of the Test of Everyday Attention to 16 individuals with molecularly confirmed FRDA and gender-, age-, and IQ-matched controls. Clinically significant impairment in working memory and sustained volitional attention was evident. Working memory deficits correlated significantly with GAA repeat number on the shorter allele of the FXN gene, and separately, with disease severity, as measured by the Friedreich Ataxia Rating Scale score. Sustained volitional attention was not correlated with disease parameters, suggesting that this impairment may not be related to the disease process in a simple way. The deficits observed may be the result of disruption to corticocerebellar pathways, or directly related to the cortical and/or cerebellar pathology evident in people with FRDA.

Entities:  

Mesh:

Year:  2010        PMID: 21083965     DOI: 10.1017/S1355617710001347

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  10 in total

1.  Personality and Neuropsychological Profiles in Friedreich Ataxia.

Authors:  Sabrina Sayah; Jean-Yves Rotgé; Hélène Francisque; Marcela Gargiulo; Virginie Czernecki; Damian Justo; Khadija Lahlou-Laforet; Valérie Hahn; Massimo Pandolfo; Antoine Pelissolo; Philippe Fossati; Alexandra Durr
Journal:  Cerebellum       Date:  2018-04       Impact factor: 3.847

2.  Measuring Inhibition and Cognitive Flexibility in Friedreich Ataxia.

Authors:  Louise A Corben; Felicity Klopper; Monique Stagnitti; Nellie Georgiou-Karistianis; John L Bradshaw; Gary Rance; Martin B Delatycki
Journal:  Cerebellum       Date:  2017-08       Impact factor: 3.847

Review 3.  Clinical features of Friedreich ataxia.

Authors:  Martin B Delatycki; Louise A Corben
Journal:  J Child Neurol       Date:  2012-06-29       Impact factor: 1.987

4.  Cognition in Friedreich ataxia.

Authors:  Antonieta Nieto; Rut Correia; Erika de Nóbrega; Fernando Montón; Stephany Hess; Jose Barroso
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

5.  Cognition in late-onset Friedreich ataxia.

Authors:  Antonieta Nieto; Rut Correia; Erika de Nóbrega; Fernando Montón; Jose Barroso
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

6.  Friedreich ataxia: executive control is related to disease onset and GAA repeat length.

Authors:  Wolfgang Nachbauer; Thomas Bodner; Sylvia Boesch; Elfriede Karner; Andreas Eigentler; Lisa Neier; Thomas Benke; Margarete Delazer
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

7.  Fronto-cerebellar dysfunction and dysconnectivity underlying cognition in friedreich ataxia: The IMAGE-FRDA study.

Authors:  Ian H Harding; Louise A Corben; Elsdon Storey; Gary F Egan; Monique R Stagnitti; Govinda R Poudel; Martin B Delatycki; Nellie Georgiou-Karistianis
Journal:  Hum Brain Mapp       Date:  2015-10-27       Impact factor: 5.038

Review 8.  Friedreich Ataxia: current status and future prospects.

Authors:  Katrin Bürk
Journal:  Cerebellum Ataxias       Date:  2017-04-07

9.  Cognitive and functional connectivity alterations in Friedreich's ataxia.

Authors:  Sirio Cocozza; Teresa Costabile; Enrico Tedeschi; Filomena Abate; Camilla Russo; Agnese Liguori; Walter Del Vecchio; Francesca Paciello; Mario Quarantelli; Alessandro Filla; Arturo Brunetti; Francesco Saccà
Journal:  Ann Clin Transl Neurol       Date:  2018-04-14       Impact factor: 4.511

10.  The cognitive profile of Friedreich ataxia: a systematic review and meta-analysis.

Authors:  Gilles Naeije; Jörg B Schulz; Louise A Corben
Journal:  BMC Neurol       Date:  2022-03-17       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.